Carl H June

Carl H June

UNVERIFIED PROFILE

Are you Carl H June?   Register this Author

Register author
Carl H June

Carl H June

Publications by authors named "Carl H June"

Are you Carl H June?   Register this Author

100Publications

4212Reads

12Profile Views

Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.

Blood 2020 Jan 17. Epub 2020 Jan 17.

Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019002779DOI Listing
January 2020

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

J Clin Oncol 2019 Dec 9:JCO1901892. Epub 2019 Dec 9.

Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01892DOI Listing
December 2019

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Mol Ther 2019 11 30;27(11):1919-1929. Epub 2019 Jul 30.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15250016193032
Publisher Site
http://dx.doi.org/10.1016/j.ymthe.2019.07.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838875PMC
November 2019

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.

Front Immunol 2018 26;9:2486. Epub 2018 Oct 26.

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02486
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02486DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212550PMC
September 2019

Emerging Use of CRISPR Technology - Chasing the Elusive HIV Cure.

Authors:
Carl H June

N Engl J Med 2019 09 11;381(13):1281-1283. Epub 2019 Sep 11.

From the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1910754DOI Listing
September 2019

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.

Cell 2019 Aug;178(4):933-948.e14

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.07.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830508PMC
August 2019

Boosting engineered T cells.

Science 2019 07;365(6449):119-120

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aax6331DOI Listing
July 2019

Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.

CPT Pharmacometrics Syst Pharmacol 2019 May 7;8(5):285-295. Epub 2019 Mar 7.

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/psp4.12388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539725PMC
May 2019

Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

Clin Cancer Res 2019 04 16;25(7):2042-2048. Epub 2018 Nov 16.

Duke Brain Tumor Immunotherapy Program, Duke University Medical Center and Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-1625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445734PMC
April 2019

Emerging Cellular Therapies for Cancer.

Annu Rev Immunol 2019 04 10;37:145-171. Epub 2018 Dec 10.

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-immunol-042718-041407DOI Listing
April 2019

Delivery technologies for cancer immunotherapy.

Nat Rev Drug Discov 2019 03;18(3):175-196

Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41573-018-0006-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410566PMC
March 2019

iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity.

Genome Biol 2019 01 17;20(1):14. Epub 2019 Jan 17.

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA, 19104-6076, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13059-019-1625-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337799PMC
January 2019

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Cytotherapy 2018 12 29;20(12):1415-1418. Epub 2018 Oct 29.

Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14653249183063
Publisher Site
http://dx.doi.org/10.1016/j.jcyt.2018.10.003DOI Listing
December 2018

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.

Leukemia 2018 11 12;32(11):2307-2315. Epub 2018 Oct 12.

CHU Rennes, Service Hématologie Clinique, 35033, Rennes, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0285-8
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0285-8DOI Listing
November 2018

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Neuro Oncol 2018 10;20(11):1429-1438

Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/20/11/1429/4
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176794PMC
October 2018

Glycan-directed CAR-T cells.

Glycobiology 2018 09;28(9):656-669

Center of Cellular Immunotherapies, Abramson Cancer Center and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/glycob/cwy008DOI Listing
September 2018

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Gastroenterology 2018 07 20;155(1):29-32. Epub 2018 Mar 20.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2018.03.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035088PMC
July 2018

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

Mol Ther 2018 07 8;26(7):1855-1866. Epub 2018 May 8.

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Parker Institute for Cancer at the University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Smilow Center for Translational Research, 3400 Civic Center Blvd., Philadelphia, PA 19104-5156, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15250016183020
Publisher Site
http://dx.doi.org/10.1016/j.ymthe.2018.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037129PMC
July 2018

Chimeric Antigen Receptor Therapy.

N Engl J Med 2018 07;379(1):64-73

From the Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (C.H.J.); and the Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York (M.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1706169DOI Listing
July 2018

Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Mol Ther 2018 06 19;26(6):1401-1403. Epub 2018 May 19.

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2018.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986966PMC
June 2018

Driving cars to the clinic for solid tumors.

Gene Ther 2018 06 7;25(3):165-175. Epub 2018 Jun 7.

Center for Cellular Immunotherapies, Abramson Cancer Center and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41434-018-0007-x
Publisher Site
http://dx.doi.org/10.1038/s41434-018-0007-xDOI Listing
June 2018

Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.

Methods Mol Biol 2017 ;1633:267-276

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7142-8_17DOI Listing
May 2018

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Cancer Immunol Res 2018 05 27;6(5):605-616. Epub 2018 Mar 27.

Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-17-0314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688490PMC
May 2018

CAR T cell immunotherapy for human cancer.

Science 2018 03;359(6382):1361-1365

Center for Cellular Immunotherapies, Perlman School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.sciencemag.org/lookup/doi/10.1126/science.aar6711
Publisher Site
http://dx.doi.org/10.1126/science.aar6711DOI Listing
March 2018

Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA.

Methods Mol Biol 2017 ;1584:443-450

Center for Cellular Immunotherapies and Department of Pathology and Laboratory Medicine Perelman School of Medicine, University of Pennsylvania, SPE 8-101 South Tower, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-6881-7_27
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-6881-7_27DOI Listing
February 2018

CAR T-Cell Therapies in Glioblastoma: A First Look.

Clin Cancer Res 2018 02 20;24(3):535-540. Epub 2017 Nov 20.

Center for Cellular Immunotherapies and Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-2871DOI Listing
February 2018

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

N Engl J Med 2018 02;378(5):439-448

From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia (S.L.M., S.A.G.) - all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, and the Pauline Allen Gill Center for Cancer and Blood Disorders, Children's Health, Dallas (T.W.L.); the Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo (J.B.); the Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu Barcelona, Barcelona (S.R.); the Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City (M.B.); the Department of Pediatrics, Faculty of Medicine, University of Montreal, and the Hematology Oncology Division and Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal (H.B.), and the Division of Haematology/Oncology/Bone Marrow Transplantation, Hospital for Sick Children, Toronto (J.K.) - all in Canada; the Division of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany (P.B.); the Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis (M.R.V., H.E.S.); Children's Mercy Hospital and Clinics, Kansas City, MO (G.D.M.); Aflac Cancer and Blood Disorders Center, Emory University, Atlanta (M.Q.); the Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, and the Cancer Research Institute Ghent (CRIG), Ghent, Belgium (B.D.M.); the Department of Pediatrics, Graduate School of Medicine Kyoto University, Kyoto, Japan (H.H.); the Department of Pediatrics, Stanford University School of Medicine, Stanford (K. Schlis, K.L.D.), and the Division of Hematology, Oncology, Blood and Marrow Transplant, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles (M.A.P.) - all in California; the Division of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, NC (P.L.M.); Oregon Health and Science University, Portland (E.R.N.); C.S. Mott Children's Hospital, Ann Arbor, MI (G.A.Y.); the Stem Cell Transplantation Unit, St. Anna Children's Hospital, Vienna (C.P.); University Hospital Robert Debré and University Paris Diderot (A. Baruchel), and Saint-Louis Hospital and University Paris Diderot (N.B.), Paris; the Royal Children's Hospital, Melbourne, VIC, Australia (F.M.); Clinica Pediatrica Universita degli Studi di Milano Bicocca, Monza, Italy (A. Balduzzi); and Novartis Pharmaceuticals (P.W., T.T., M.L., Y.Z., K. Sen, D.L.) and Novartis Institutes for Biomedical Research (K.T.M.) - both in East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709866DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996391PMC
February 2018

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Mol Ther 2018 01 12;26(1):280-288. Epub 2017 Sep 12.

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2017.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762981PMC
January 2018

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Mol Ther 2018 01 20;26(1):269-279. Epub 2017 Oct 20.

Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2017.10.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763152PMC
January 2018

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Curr Hematol Malig Rep 2017 12;12(6):522-529

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0417-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709224PMC
December 2017

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

N Engl J Med 2017 12 10;377(26):2545-2554. Epub 2017 Dec 10.

From the Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L., J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (Ö.A.); and Novartis Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708566
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788566PMC
December 2017

Immunotherapy for Breast Cancer: Current and Future Strategies.

Curr Surg Rep 2017 Dec 10;5. Epub 2017 Oct 10.

Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th floor South, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894864PMC
http://dx.doi.org/10.1007/s40137-017-0194-1DOI Listing
December 2017

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Cancer Discov 2017 10 2;7(10):1154-1167. Epub 2017 Jun 2.

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628114PMC
October 2017

Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment.

Cell Stem Cell 2017 10;21(4):427-430

University of California, Davis, Institute for Regenerative Cures (IRC), Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2017.09.007DOI Listing
October 2017

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.

Cell Rep 2017 Sep;20(13):3025-3033

Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002762PMC
September 2017

Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.

Protein Cell 2017 07 18;8(7):514-526. Epub 2017 May 18.

Center for Cellular Immunotherapies, University of Pennsylvania Cancer Center, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13238-017-0422-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498341PMC
July 2017

Immunotherapy for Brain Tumors.

J Clin Oncol 2017 Jul 22;35(21):2450-2456. Epub 2017 Jun 22.

John H. Sampson, Duke University, Durham, NC; Marcela V. Maus, Massachusetts General Hospital and Harvard Medical School, Boston, MA; and Carl H. June, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.8089DOI Listing
July 2017

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.

Clin Cancer Res 2017 May 4;23(9):2255-2266. Epub 2016 Nov 4.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413401PMC
May 2017

Is autoimmunity the Achilles' heel of cancer immunotherapy?

Nat Med 2017 05;23(5):540-547

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4321DOI Listing
May 2017

Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.

Cancer Res 2017 04 31;77(8):2052-2063. Epub 2017 Jan 31.

ProCure Program, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-1708DOI Listing
April 2017

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

J Immunother 2017 04;40(3):104-107

*Department of Obstetrics and Gynecology ‡Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia †Department of Obstetrics and Gynecology, Lancaster General Health/Penn Medicine, Lancaster, PA §Department of Medicine and Cancer Center, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000160DOI Listing
April 2017

A versatile system for rapid multiplex genome-edited CAR T cell generation.

Oncotarget 2017 Mar;8(10):17002-17011

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370017PMC
March 2017

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Crit Care Med 2017 Feb;45(2):e124-e131

1Division of Critical Care Medicine, Department of Anesthesia and Critical Care, The Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 2Division of Oncology, Department of Pediatrics, The Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3Center for Cellular Immunotherapies, Department of Pathology and Laboratory Medicine, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 4Department of Biostatistics and Epidemiology, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 5Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000002053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452983PMC
February 2017

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Blood 2017 02 28;129(8):1039-1041. Epub 2016 Dec 28.

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-09-738245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391777PMC
February 2017

The Principles of Engineering Immune Cells to Treat Cancer.

Cell 2017 02;168(4):724-740

Center for Cellular Immunotherapies, the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine, and the Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.01.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553442PMC
February 2017

Cancer Killers.

Sci Am 2017 Feb;316(3):38-43

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/scientificamerican0317-38DOI Listing
February 2017

Driving gene-engineered T cell immunotherapy of cancer.

Cell Res 2017 Jan 27;27(1):38-58. Epub 2016 Dec 27.

Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cr.2016.154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223234PMC
January 2017

Drugging the Undruggable Ras - Immunotherapy to the Rescue?

Authors:
Carl H June

N Engl J Med 2016 12;375(23):2286-2289

From the Center for Cellular Immunotherapies, the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine, and the Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1612215DOI Listing
December 2016

Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.

J Am Acad Dermatol 2016 Nov;75(5):1054-1057

Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2016.06.062DOI Listing
November 2016

Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety.

Immunity 2016 11;45(5):947-948

Center for Cellular Immunotherapies and Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, PA, 19104-5156 USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2016.10.015DOI Listing
November 2016

Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.

Curr Hematol Malig Rep 2016 10;11(5):368-84

Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-016-0336-zDOI Listing
October 2016

miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Blood 2016 09 2;128(10):1424-35. Epub 2016 Aug 2.

Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-05-714535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016708PMC
September 2016

Remote Controlled CARs: Towards a Safer Therapy for Leukemia.

Authors:
Carl H June

Cancer Immunol Res 2016 08 23;4(8):643. Epub 2016 Jun 23.

Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0132DOI Listing
August 2016

Engineered T cells: the promise and challenges of cancer immunotherapy.

Nat Rev Cancer 2016 08;16(9):566-81

Department of Pathology and Laboratory Medicine and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-5156, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.97DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543811PMC
August 2016

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Oncoimmunology 2016 May 19;5(5):e1062210. Epub 2015 Oct 19.

Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA; Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University Hospital of Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1062210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910715PMC
May 2016